Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study

IMPORTANCE: The development of new primary cutaneous melanoma (CM) after starting immune checkpoint inhibitor (ICI) therapy is poorly characterized. OBJECTIVE: To determine the incidence of new CM in patients treated with ipilimumab, nivolumab, and/or pembrolizumab for metastatic melanoma. DESIGN, S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Dermatol
Main Authors: Nanda, Japbani K., Dusza, Stephen W., Navarrete-Dechent, Cristian, Liopyris, Konstantinos, Marghoob, Ashfaq A., Marchetti, Michael A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7495326/
https://ncbi.nlm.nih.gov/pubmed/32936222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2020.3671
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados